References
- Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet.2, 343–372 (2001).
- von Bertalanffy L. General Systems Theory. George Braziller, NY, USA (1969).
- Searls DB. Data integration: challenges for drug discovery. Nat. Rev. Drug Discov.4, 45–48 (2005).
- FitzGerald GA. Anticipating change in drug development: the emerging era of translational medicine and therapeutics. Nat. Rev. Drug Discov.4, 815–818 (2005).
- US FDA. Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. US FDA, USA (2004).
- Kacser H. On parts and wholes in metabolism. In: The Organization of Cell Metabolism. Welch GR, Clegg JS (Eds), Plenum Press, NY, USA (1986).
- Cascante M, Boros LG, Comin-Anduix B et al. Metabolic control analysis in drug discovery and disease. Nat. Biotechnol.20, 243–249 (2002).
- Kell DB. Metabolomics, modelling and machine learning in systems biology – towards an understanding of the languages of cells. Delivered on 3 July 2005 at the 30th FEBS Congress and 9th IUBMB conference in Budapest. FEBS J.273, 873–894 (2006).
- van der Greef J, Davidov E, Verheij E et al The role of metabolomics in systems biology: a new vision for drug discovery and development. In: Metabolic profiling: its role in biomarker discovery and gene function analysis. Harrigan GG, Goodacre R (Eds), Kluwer Academic Publishers, MA, USA 171–198 (2003).
- Nicholson JK, Wilson ID. Understanding ‘global’ systems biology: metabolonomics and the continuum of metabolism. Nat. Rev. Drug Discov.2, 668–676 (2003).
- Raamsdonk LM, Teusink B, Broadhurst D et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat. Biotechnol.19, 45–50 (2001).
- Oresic M, Clish CB, Davidov EJ et al. Phenotype characterization using integrated gene transcript, protein and metabolite profiling. Appl. Bioinformatics3, 205–217 (2004).
- Nicholson JK, Connely J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov.1, 153–161 (2002).
- van der Greef J, Stroobant P, van der Heijden R. The role of analytical sciences in medical systems biology. Curr. Opin. Chem. Biol.8, 559–565 (2004).
- Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas–liquid partition chromatography. Proc. Natl Acad. Sci. USA68, 2374–2376 (1971).
- de Hoffmann E, Stroobant V. Mass Spectrometry: Principles and Applications. John Wiley & Sons (2001).
- Lindon JC, Holmes E, Nicholson JK. Metabonomics and its role in drug development and disease diagnosis. Expert Rev. Mol. Diagn.4, 189–199 (2004).
- Ardrey RE. Liquid Chromatography-Mass Spectrometry: an Introduction. John Wiley & Sons (2003).
- Katajamaa M, Oresic M. Processing methods for differential analysis of LC/MS profile data. BMC Bioinformatics6, 179 (2005).
- Katajamaa M, Miettinen J, Oresic M. MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data. Bioinformatics22, 634–636 (2006).
- Stolt R, Torgrip RJO, Lindberg J et al. Second-order peak detection for multicomponent high-resolution LC/MS data. Anal. Chem.78, 975–983 (2006).
- Bijlsma S, Bobeldijk I, Verheij ER et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal. Chem.78, 567–574 (2006).
- Prakash A, Mallick P, Whiteaker J et al. Signal maps for mass spectrometry-based comparative proteomics. Mol. Cell. Proteomics5, 423–432 (2006).
- Davidov E, Clish CB, Oresic M et al. Methods for the differential integrative omic analysis of plasma from a transgenic disease animal model. Omics8, 267–288 (2004).
- Crockford DJ, Holmes E, Lindon JC et al. Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal. Chem.78, 363–371 (2006).
- Smilde AK, van der Werf MJ, Bijlsma S, van der Werff-van der Vat BJ, Jellema RH. Fusion of mass spectrometry-based metabolomics data. Anal. Chem.77, 6729–6736 (2005).
- Oksman-Caldentey K-M, Inze D, Oresic M. Connecting genes to metabolites by a systems biology approach. Proc. Natl Acad. Sci. USA101, 9949–9950 (2004).
- Brazma A, Hingamp P, Quackenbush J et al. Minimum information about microarray experiment (MIAME) – towards standards for microarray data. Nat. Genet.29, 365–371 (2001).
- The Standard Metabolic Reporting Structures Working Group. Summary recommendations for standardization and reporting of metabolic analyses. Nat. Biotechnol.23, 833–838 (2005).
- Lagarde M, Geloen A, Record M, Vance D, Spener F. Lipidomics is emerging. Biochim. Biophys. Acta1634, 61 (2003).
- Wenk MR. The emerging field of lipidomics. Nat. Rev. Drug Discov.4, 594–610 (2005).
- Ekroos K, Chernushevich IV, Simons K, Shevchenko A. Quantitative profiling of phospholipids by multiple precursor ion scanning on a hybrid quadrupole time-of-flight mass spectrometer. Anal. Chem.74, 941–949 (2002).
- Han X, Gross RW. Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics. J. Lipid Res.44, 1071–1079 (2003).
- Schwudke D, Oegema J, Burton L et al. Lipid profiling by multiple precursor and neutral loss scanning driven by the data-dependent acquisition. Anal. Chem.78, 585–595 (2006).
- McAnoy AM, Wu CC, Murphy RC. Direct qualitative analysis of triacylglycerols by electrospray mass spectrometry using a linear ion trap. J. Am. Soc. Mass Spectrom.16, 1498–1509 (2005).
- Hermansson M, Uphoff A, Kakela R, Somerharju P. Automated quantitative analysis of complex lipidomes by liquid chromatography/mass spectrometry. Anal. Chem.77, 2166–2175 (2005).
- Houjou T, Yamatani K, Imagawa M, Shimizu T, Taguchi R. A shotgun tandem mass spectrometric analysis of phospholipids with normal-phase and/or reverse-phase liquid chromatography/electrospray ionization mass spectrometry. Rapid Comm. Mass Spectrom.19, 654–666 (2005).
- Taguchi R, Houjou T, Nakanishi H et al. Focused lipidomics by tandem mass spectrometry. J. Chromatogr. B823, 26–36 (2005).
- Ishida M, Yamazaki T, Houjou T et al. High-resolution analysis by nano-electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry for the identification of molecular species of phospholipids and their oxidized metabolites. Rapid Comm. Mass Spectrom.18, 2486–2494 (2004).
- Fahy E, Subramaniam S, Brown HA et al. A comprehensive classification system for lipids. J. Lipid Res.46, 839–862 (2005).
- Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol.3, 431–438 (2005).
- Robosky LC, Wells DF, Egnash LA et al. Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol. Sci.87, 277–284 (2005).
- Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucl. Acids Res.32, D267–D270 (2004).
- Wheeler DL, Church DM, Edgar R et al. Database resources of the National Center for Biotechnology Information: update. Nucl. Acids Res.32, D35–D40 (2004).
- Butte AJ, Kohane IS. Creation and implications of a phenome–genome network. Nat. Biotechnol.24, 55–62 (2006).
- Anthony JC, Eaton WW, Henderson AS. Looking to the future in the psychiatric epidemiology. Epidemiol. Rev.17, 240–242 (1995).
- Freimer N, Sabatti C. The Human Phenome Project. Nat. Genet.34, 15–21 (2003).
- Brindle JT, Antti H, Holmes E et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med.8, 1439–1445 (2002).
- Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer4, 309–314 (2004).
- Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer5, 142–149 (2005).
- Lenz EM, Bright J, Wilson ID et al. Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal.36, 841–849 (2004).
- Bollard ME, Stanley EG, Lindon JC, Nicholson JK, Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed.18, 143–162 (2005).
- Kupila A, Muona P, Simell T et al. Feasibility of genetic and immunological prediction of Type I diabetes in a population-based birth cohort. Diabetologia44, 290–297 (2001).
- Almind K, Kahn CR. Genetic determinants of energy expenditure and insulin resistance in obesity in mice. Diabetes53, 3274–3285 (2004).
- Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science274, 1704–1707 (1996).
- Medina-Gomez G, Virtue S, Lelliott C et al. The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-γ2 isoform. Diabetes54, 1706–1716 (2005).
- Barker M, Rayens W. Partial least squares for discrimination. J. Chemometrics17, 166–173 (2003).
- Hastie T, Tibshirani R, Friedman JH. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. Springer Verlag, NY, USA (2001).
- Li Z, Chan C. Integrating gene expression and metabolic profiles. J. Biol. Chem.279, 27124–27137 (2004).
- Griffin JL, Bonney SA, Mann C et al. An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver. Physiol. Genomics17, 140–149 (2004).
- Lelliott CJ, Lopez M, Curtis RK et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J.19, 1108–1119 (2005).
- Clish C, Davidov E, Oresic M et al. Integrative biological analysis of the ApoE3–Leiden transgenic mouse. Omics8, 3–13 (2004).
- Ashburner M, Ball C, Blake J et al. Gene ontology: tool for the unification of biology. Nat. Genet.25, 25–29 (2000).
- Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucl. Acids Res.32, D277–D280 (2004).
- Clayton TA, Lindon JC, Cloarec O et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature440, 1073–1077 (2006).
- Lindon JC, Keun HC, Ebbels TM et al. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics6, 691–699 (2005).
- van der Greef J, McBurney R. Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov.4, 961–967 (2005).
Websites
- US FDA: Division of Systems Toxicology www.fda.gov/nctr/science/divisions/systemstoxicology.htm (Viewed May 2006)
- The Metabolomics Society www.metabolomicssociety.org (Viewed May 2006)
- LIPID Metabolites And Pathways Strategy www.lipidmaps.org (Viewed May 2006)
- HUSERMET Project: the human serum metabolome in health and disease www.metabolomics.co.uk (Viewed May 2006)